Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
IDHIRA: A prospective, multicenter, non-interventional study of ivosidenib in patients with IDH1 R132-mutated cholangiocarcinoma

Michl M, Hagemeyer N, Grebhardt S, Looss, M, Potthoff K, 2024, AbstractID: AS-DGHO-2024-00336 Posternumber: P1098

Download

Indikation: Cholangiocarcinoma / Veranstaltung: DGHO / Journal:
IDHIRA
2024
Progression-free and overall survival of patients with SCLC and ECOG performance status 0-1 – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-) Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

Waller, C.F.; Fischer, R.; Reck, M.; Gauler, T.; Christopoulos, P., Bruch, H.-R. Grah, C.; Ludwig, P.; Hipper, A.; Medinger, T.; Tech, S.; Binninger, A.; Jänicke, M.; Elender, C.; Christoph, D.C.; Griesinger, F.; Thomas, M.; Eberhardt, W.E.E.; Sebastian, M., 2024, Annual Meeting DGHO, Poster-Nr. P448

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal:
CRISP
2024
Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior anti-HER2 treatment regimens: Study design of the non-interventional study TRACE in Germany and Austria

Arnd Nusch A, Angerer M, Kreiss-Sender J, Radosa J, Uleer C, Wrobel D, Balic M, Egle D, Harbeck N, Müller V, Schumacher-Wulf E, de Buhr R, Glasstetter M, Hanselmann J, Salb C, Marschner N, Gratzke K, Bartsch R, Welt A

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal:
TRACE
2024
Changes in survival of >3.800 patients with metastatic colorectal cancer in Germany: Results from 16-year prospective longitudinal real-world data analysis

Marschner N, Seufferlein T, Potthoff K, Zahn MO, Uhlig J, Dörfel S, Karcher A, Sauer A, Maintz C, Fruehauf S, Hutzschenreuter U, Tech S, Grafetstätter M, Kruggel L, Jänicke M.
ESMO Real World, Volume 4, Issue C, 2024. https://doi.org/10.1016/j.esmorw.2024.100040

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: ESMO Real World
TKK
2024
Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.

Marschner N, Knauf W.
Oncol Res Treat. 2024 Mar 15:1-11.
doi: 10.1159/000536652. Epub ahead of print.

Abstract

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Oncology Research and Treatment
Indikationsübergreifend, Registerübergreifend
2024
Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior ant-HER2 treatment regimens. Study Design of the non-interventional study TRACE in Germany and Austria.

A Nusch, M Angerer, M Welslau, C Uleer, J Radosa, D Wrobel, S Noeding, K Apel, J Terhaag, I Tamm, L Bauer, M Balic, D Egle, N Harbeck, V Müller, E Schumacher-Wulf, R de Buhr, M Glasstetter, J Hanselmann, C Hogrefe, N Marschner, K Gratzke, R Bartsch, A Welt.

Oncol Res Treat (2024) 47 (Suppl. 1): 7–283. https://doi.org/10.1159/000535363 Abstract 49, Seite 28

Download
Link

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
TRACE
2024
Palbociclib versus ribociclib in first-line treatment of patients with hormone-receptor positive HER2 negative advanced breast cancer – real world outcome data from the German registry platform OPAL

Thill M., Zahn M.-O., Welt A., Nusch A., Zaiss M., Engelken K., Kaltenecker G., Ringwald K., Gratzke K., Kruggel L., Jänicke M., Schulz H., Losem C., Hagen V., Fricker R., Stickeler E., Harbeck N., Wöckel A., Decker T.. PO1-04-12

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal:
OPAL
2023
Palbociclib plus endocrine therapy in HR+/HER2- Advanced Breast Cancer patients: Interim Results of the PERFORM study

Radosa J., Fietz T., Wilke J., Decker T., Petersen V., Deryal M., Knoblich J., Losem C., Rhein U., Schöttker B., Wrobel D., Pfeiler G., Zanucco E., Buncke J., Frank M., Woerner S.M., Gratzke, K., Adams, A., Glastetter E., Bartsch R., Lux M.P.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal:
PERFORM
2023
Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE

Reiser M, Marschner N, Uhlig J, Jacobasch L, Müller L, Schuch A, Serrer L, de Buhr RK, Siebenbach HU, Göhler T, Schröder J, Semsek D, Köhler A, Stübs P, Potthoff K

Download

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ESMO / Journal:
VALIDATE
2023
Survival in patients with advanced renal cell carcinoma in the era of immunotherapies: first data from the German research platform CARAT

Goebell P.J., Bögemann M., Nusch A., Grünwald V., Müller L., von der Heyde E., Reichert D., Martens U.M., Grüllich C., Staehler M., Wetzel N., Koska M., Jänicke M., Marschner N., Potthoff K.

Oncol Res Treat. 2023;46 (Suppl. 5)(V510):76-77

Link

Indikation: Nierenzellkarzinom, Renal Cell Carcinoma / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARAT
2023